1. Median overall survival is longer for HER2-low breast cancer patients receiving trastuzumab deruxtecan compared with other chemotherapy treatment options....
1. All neoadjuvant dostarlimab patients had a clinical complete response and no patients needed any additional treatments at the study...
1. Reduced median overall survival associated with annual rate of change in circulating tumour cell (CTC) abundance >0.12 CTCs/mL 2....
1. The median progression-free survival was marginally increased in the atezolizumab group. 2. Adverse events of grades 3 and 4...
1. Neoadjuvant nivolumab plus chemotherapy led to a longer event-free survival and higher percentage of patients with a pathological complete...
1. Disease-free survival did not differ significantly between patient groups and overall survival at 3 years was the same for...
1. In this systematic review and meta-analysis, medical cannabis and cannabinoids versus placebo were found to provide a small increase...
1. 5-year progression-free status was greatest in group 3 (triple therapy) and lowest in group 1 (pelvic bed radiotherapy alone)....
1. The adebrelimab group had an improved overall survival, higher objective response rate and an increased progression-free survival. 2. Adverse...
1. Progression-free survival was longer for patients receiving tiragolumab with atezolizumab as compared to placebo 2. The combination arm had...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.